

**Project ECHO for Interstitial Lung Disease**

Wednesday, July 15, 2026, 7am-8am ET

|                        |                                                                                                                  |
|------------------------|------------------------------------------------------------------------------------------------------------------|
| Medical Director       | Robert Hallowell, MD                                                                                             |
| Principal Investigator | Aliaa Barakat, PhD                                                                                               |
| Didactic Speaker       | Barry Shea, MD                                                                                                   |
| Discussion Facilitator | Sydney Montesi, MD                                                                                               |
| Target Audience        | The series is designed for pulmonologists, radiologists and other health providers who care for people with ILD. |

**In accordance with HIPAA:** All PHI will be de-identified during the session.

| Time          | Didactic Presentation / Case Discussion                        | Presenter / Facilitator                    |
|---------------|----------------------------------------------------------------|--------------------------------------------|
| 7:00am-7:05am | Announcements and Introductions                                | Aliaa Barakat, PhD<br>Robert Hallowell, MD |
| 7:05am-7:25am | Didactic: More Than Meds — Nonpharmacologic Treatments for ILD | Barry Shea, MD                             |
| 7:25am-8:00am | Case Presentation and Discussion                               | Sydney Montesi, MD                         |
| 8am           | Closing Remarks                                                | Robert Hallowell, PhD                      |

**Didactic Learning Objectives:**

1. Understand the role that pulmonary rehab plays in improving quality of life in ILDs.
2. Describe the evidence supporting the use of supplemental oxygen for ILD patients with isolated exertional hypoxemia.
3. Understand the barriers to supplemental oxygen use.

ECHO case discussions are intended solely for educational purposes and are not meant to serve as a consultation or as a mechanism for providing formal recommendations on treatment and other management decisions, which remain the sole responsibility of the treating provider.

This session will be audio and video recorded.  
Your participation confirms your consent to this recording.

**Chobanian & Avedisian School of Medicine**

Barry M. Manuel Center for Continuing Education



In support of improving patient care, this activity has been planned and implemented by the ILD Collaborative and Boston University Chobanian & Avedisian School of Medicine. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**American Board of Internal Medicine Maintenance of Certification (MOC) Part 2 Credit**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 22.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**American Board of Pathology Maintenance of Certification (MOC) Part 2 Credit**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 22.0 MOC points in the American Board of Pathology's (ABPath) Maintenance of Certification (MOC) program. Credit type: Lifelong Learning (CME).

*By participating and claiming credit, you grant the Center for Continuing Education permission to submit your information to the ACCME, the conduit to the ABIM and ABPath.*

**Physician Accreditation**

Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurse Accreditation**

Nursing Contact Hours: 1.0, all of which is eligible for pharmacology credit.

This activity is supported by the ILD Collaborative and by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

This session will be audio and video recorded.  
Your participation confirms your consent to this recording.

## Disclosure Policy

Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

None of the following planners / presenters for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Aliaa Barakat, PhD, Katharine Black, MD, Fiona Gibbons, MD, and Grace Peloquin, MD.

The following planners / presenters listed below have disclosed that they have a relevant financial relationship with an ineligible company.

| Name                 | Disclosure of Relevant Financial Relationship                                                                                                                                                                                                                                                                             |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Leo Ginns, MD        | Dr. Ginns is a clinical trial site principal investigator for United Therapeutics.                                                                                                                                                                                                                                        |
| Robert Hallowell, MD | Dr. Hallowell has served on advisory boards and as an investigator for Boehringer Ingelheim. He has served as a consultant and an investigator for Vicore. He has also been a consultant for Merck and receives authorship fees from Up-to-Date and Dynamed. He is also on the advisory boards for Arcellx and Puretech.  |
| Sydney Montesi, MD   | Dr. Montesi is a consultant and on the clinical adjudication committee for AbbVie. She is also a consultant for Amgen, Accendatech, and Mediar Therapeutics. She receives research funding from Boehringer Ingelheim, and Pliant Therapeutics via her institution. She also receives authorship fees from Wolters Kluwer. |
| Barry Shea, MD       | Dr. Shea is a clinical trial site principal investigator for Boehringer Ingelheim, Bristol Myers Squibb, and Mediar Therapeutics. He has served as a consultant for Continuum Therapeutics, Radius Health, and United Therapeutics.                                                                                       |

All of the relevant financial relationships listed for these individuals have been mitigated.

The faculty does plan on discussing unlabeled/investigational uses of a commercial product.

### Accreditor Disclosure:

Michael Burk, Senior Operations Manager for Boston University Chobanian & Avedisian School of Medicine Center for Continuing Education, has no relevant financial relationships to disclose.